Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer.
Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, Raz DJ, Reckamp KL, Merritt RE, Owen DH, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doebele RC, Baciewicz F, Nagasaka M, Pass HI, Schulze K, Johnson A, Bunn PA, Johnson BE, Kris MG, Kwiatkowski DJ, Wistuba II, Chaft JE, Carbone DP, Lee JM.
Rusch VW, et al. Among authors: blasberg jd.
J Thorac Cardiovasc Surg. 2023 Mar;165(3):828-839.e5. doi: 10.1016/j.jtcvs.2022.10.007. Epub 2022 Oct 8.
J Thorac Cardiovasc Surg. 2023.
PMID: 36369159
Free PMC article.
Clinical Trial.